156 related articles for article (PubMed ID: 25219760)
1. Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patients.
Devillier R; Gelsi-Boyer V; Murati A; Prebet T; Rey J; Etienne A; D'Incan E; Charbonnier A; Blaise D; Mozziconacci MJ; Vey N
Am J Hematol; 2015 Jan; 90(1):E22-4. PubMed ID: 25219760
[No Abstract] [Full Text] [Related]
2. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
[TBL] [Abstract][Full Text] [Related]
3. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
Haferlach C; Bacher U; Schnittger S; Alpermann T; Zenger M; Kern W; Haferlach T
Genes Chromosomes Cancer; 2012 Apr; 51(4):328-37. PubMed ID: 22162288
[TBL] [Abstract][Full Text] [Related]
4. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.
Schnittger S; Eder C; Jeromin S; Alpermann T; Fasan A; Grossmann V; Kohlmann A; Illig T; Klopp N; Wichmann HE; Kreuzer KA; Schmid C; Staib P; Peceny R; Schmitz N; Kern W; Haferlach C; Haferlach T
Leukemia; 2013 Jan; 27(1):82-91. PubMed ID: 23018865
[TBL] [Abstract][Full Text] [Related]
5. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system.
Weinberg OK; Seetharam M; Ren L; Seo K; Ma L; Merker JD; Gotlib J; Zehnder JL; Arber DA
Blood; 2009 Feb; 113(9):1906-8. PubMed ID: 19131546
[TBL] [Abstract][Full Text] [Related]
6. Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells.
Bacher U; Haferlach C; Alpermann T; Kern W; Schnittger S; Haferlach T
Haematologica; 2011 Sep; 96(9):1284-92. PubMed ID: 21606170
[TBL] [Abstract][Full Text] [Related]
7. Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1.
Rozman M; Navarro JT; Arenillas L; Aventín A; Giménez T; Alonso E; Perea G; Camós M; Navarrete M; Tuset E; Florensa L; Millá F; Nomdedéu J; de la Banda E; Díaz-Beyá M; Pratcorona M; Garrido A; Navarro B; Brunet S; Sierra J; Esteve J;
Ann Hematol; 2014 Oct; 93(10):1695-703. PubMed ID: 24824767
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients.
Xu XQ; Wang JM; Gao L; Qiu HY; Chen L; Jia L; Hu XX; Yang JM; Ni X; Chen J; Lü SQ; Zhang WP; Song XM
Am J Hematol; 2014 Sep; 89(9):874-81. PubMed ID: 24861848
[TBL] [Abstract][Full Text] [Related]
9. Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes.
Fang H; He R; Chiu A; Viswanatha DS; Ketterling RP; Patnaik MS; Reichard KK
Am J Clin Pathol; 2020 Apr; 153(5):656-663. PubMed ID: 31977035
[TBL] [Abstract][Full Text] [Related]
10. SETBP1 mutation analysis in 944 patients with MDS and AML.
Thol F; Suchanek KJ; Koenecke C; Stadler M; Platzbecker U; Thiede C; Schroeder T; Kobbe G; Kade S; Löffeld P; Banihosseini S; Bug G; Ottmann O; Hofmann WK; Krauter J; Kröger N; Ganser A; Heuser M
Leukemia; 2013 Oct; 27(10):2072-5. PubMed ID: 23648668
[No Abstract] [Full Text] [Related]
11. Multilineage dysplasia as assessed by immunophenotype has no impact on clinical-biological features and outcome of NPM1-mutated acute myeloid leukemia.
Mannelli F; Ponziani V; Bonetti MI; Bencini S; Cutini I; Gianfaldoni G; Scappini B; Pancani F; Rondelli T; Benelli M; Caporale R; Grazia Gelli AM; Peruzzi B; Longo G; Bosi A
Exp Hematol; 2015 Oct; 43(10):869-879.e22. PubMed ID: 26101160
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia with myelodysplasia-related changes diagnosed with multilineage dysplasia alone demonstrates a superior clinical outcome.
Jiang G; Capo-Chichi JM; Liu A; Atenafu EG; Guo R; Tierens A; Minden MD; Chang H
Hum Pathol; 2020 Oct; 104():117-126. PubMed ID: 32798550
[TBL] [Abstract][Full Text] [Related]
13. Impact of Molecular Sequencing Information as Related to 2008 and 2016 World Health Organization Classification of Acute Myeloid Leukemia and Myelodysplasia.
Toth LN; de Abreu FB; Peterson JD; Loo EY
Arch Pathol Lab Med; 2018 Sep; 142(9):1017. PubMed ID: 30141999
[No Abstract] [Full Text] [Related]
14. Analysis of NUP98/NSD1 translocations in adult AML and MDS patients.
Thol F; Kölking B; Hollink IH; Damm F; van den Heuvel-Eibrink MM; Michel Zwaan C; Bug G; Ottmann O; Wagner K; Morgan M; Hofmann WK; Göhring G; Schlegelberger B; Krauter J; Ganser A; Heuser M
Leukemia; 2013 Mar; 27(3):750-4. PubMed ID: 22929522
[No Abstract] [Full Text] [Related]
15. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.
Bains A; Luthra R; Medeiros LJ; Zuo Z
Am J Clin Pathol; 2011 Jan; 135(1):62-9. PubMed ID: 21173125
[TBL] [Abstract][Full Text] [Related]
16. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients.
Yang YT; Hou HA; Liu CY; Lin CC; Chou WC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Kuo YY; Huang SY; Ko BS; Chen CY; Hsu SC; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Sep; 89(9):E142-9. PubMed ID: 24845799
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.
Devillier R; Gelsi-Boyer V; Brecqueville M; Carbuccia N; Murati A; Vey N; Birnbaum D; Mozziconacci MJ
Am J Hematol; 2012 Jul; 87(7):659-62. PubMed ID: 22535592
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC).
Yun S; Sharma R; Chan O; Vincelette ND; Sallman DA; Sweet K; Padron E; Komrokji R; Lancet JE; Abraham I; Moscinski LC; Cleveland JL; List AF; Zhang L
Leuk Res; 2019 Sep; 84():106194. PubMed ID: 31357093
[TBL] [Abstract][Full Text] [Related]
19. Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia.
Estey EH; Keating MJ; Dixon DO; Trujillo JM; McCredie KB; Freireich EJ
Hematol Pathol; 1987; 1(4):203-8. PubMed ID: 3504436
[TBL] [Abstract][Full Text] [Related]
20. DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.
El Ghannam D; Taalab MM; Ghazy HF; Eneen AF
Blood Cells Mol Dis; 2014; 53(1-2):61-6. PubMed ID: 24512939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
